erevnon Posted - 1 hour ago

Mizuho maintains Cytokinetics $CYTK at Outperform and raises the price target from $99 to https://marketsblock.com/stock-upgrades-and-downgrades/

IN0V8 Posted - 1 hour ago

$CYTK Opportunity Mizuho raises target price to $103 from $99

RoyMunson69 Posted - 4 hours ago

Come back when it’s $30 $CYTK

diamondoptionsinc Posted - 20 hours ago

$CYTK very interesting $4,100,000 order came in today for the January 2026 $70 calls (the stock is currently trading under $50!) Price has filled the gap from December 2023 and seems to be basing nicely at this level. Good one to keep on your watchlists!

greenype Posted - 21 hours ago

$CYTK

TeresaTrades Posted - 22 hours ago

Heavy options volume $CYTK $TKO $PAYX $MTUM $AMCR

erevnon Posted - 1 day ago

Needham reiterates Cytokinetics $CYTK at Buy and maintains a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

anachartanalyst Posted - 1 day ago

$CYTK https://anachart.com/wp-content/uploads/ana_temp/1732096883_soc-img.jpg

zmanx Posted - 1 day ago

$CYTK nice AH’s news with $BAYRY license deal ! Still riding the 🌊 with my last few I’m holding here.

erevnon Posted - 1 day ago

HC Wainwright & Co. reiterates Cytokinetics $CYTK at Buy and maintains a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

OpenOutcrier Posted - 2 days ago

$CYTK (+1.1% pre) Bayer acquires rights to Cytokinetics' heart drug in Japan - Reuters https://ooc.bz/l/48597

DonCorleone77 Posted - 2 days ago

$CYTK $BAYRY Cytokinetics, Bayer enter collaboration and license pact for aficamten in Japan Cytokinetics (CYTK) and Bayer (BAYRY) announced they have entered into a collaboration and license agreement for the exclusive development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy, or HCM, subject to certain reserved development rights of Cytokinetics. Aficamten is a next-in-class cardiac myosin inhibitor for the potential treatment of patients with HCM. Cytokinetics will receive an upfront payment of EUR 50M and is eligible to receive up to an additional EUR 90M upon the achievement of milestones through commercial launch, including EUR 20M which are near-term. Cytokinetics is also eligible to receive up to EUR 490M in commercial milestone payments upon the achievement by Bayer of certain sales milestones, and tiered royalties on net sales of aficamten in Japan. This collaboration leverages Cytokinetics' broad development program of aficamten and Bayer's regional capabilities and expertise in the development and commercialization of therapies to treat cardiovascular diseases of unmet need for the benefit of patients in Japan. Under the joint development plan, Bayer will conduct a Phase 3 clinical trial in Japanese patients with obstructive HCM and Cytokinetics will expand ACACIA-HCM, the ongoing Phase 3 clinical trial of aficamten in patients with non-obstructive HCM, into Japan to support the potential marketing authorization of aficamten in Japan and CEDAR-HCM, its ongoing study for a pediatric population of patients with obstructive HCM.

sanmateomaverick Posted - 2 days ago

$CYTK Japan licensing deal for Aficamten secured with Bayer https://www.globenewswire.com/news-release/2024/11/19/2983285/0/en/Cytokinetics-and-Bayer-Announce-Exclusive-Licensing-Collaboration-for-Aficamten-in-Japan.html

erevnon Posted - 3 days ago

HC Wainwright & Co. reiterates Cytokinetics $CYTK at Buy and maintains a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

Nosh Posted - 5 days ago

$CYTK Watching...sooner or later it has to do something and it has held $50 well...how much longer until updates?

greenype Posted - 5 days ago

$CYTK a bit less overvalued now, more to go

Social_Idiot Posted - 5 days ago

$CYTK So volatile

Dustman16 Posted - 1 week ago

$CYTK pullback today or what’s going on?

Fishcakes123 Posted - 1 week ago

$CYTK Why are CYTK re-releasing Ph3 data from GALATIC-HF when in 2022 the results were published saying there mas no s.s. effect on peak Vo2 max compared to placebo? Have they re-run the trial?

Jmac98 Posted - 1 week ago

$CYTK

chopanosh Posted - 1 week ago

$CYTK We need more cowbell

DerexCapital Posted - 1 week ago

$CYTK buyout soon $120 🎯

muldoon92 Posted - 1 week ago

$CYTK think buyout of this is gonna be what kickstarts $XBI. Would be a nice double hitter for me 😋

chopanosh Posted - 1 week ago

$CYTK been holding and watching this one for a long time. There was a something up

hope_my_calls_print Posted - 1 week ago

$CYTK we're green. I don't trust it. Did someone finally figure out this is one of the most acquirable bolt-ons on the market and everything else is expensive as shit right now?

erevnon Posted - 1 week ago

RBC Capital initiates coverage on Cytokinetics $CYTK at Outperform rating and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

NJgolfer Posted - 1 week ago

$CYTK 43 week downtrend so almost 1 year pullback and finally showing multiple signs of buyers stepping in. Weekly RSI above 51, above 21w EMA, daily Chaikin money flow also breaking out from pullback and above all key EMAs on daily chart. I already have a large biotech allocation but $CYTK is really intriguing.

Estimize Posted - 2 weeks ago

$CYTK reports after the close, Estimize Consensus -0.02 EPS and -0.01M Revs compared to WS http://www.estimize.com/cytk/fq3-2024?utm_conten

TrendM4p Posted - 2 weeks ago

🚨 MYNZ HUGE PR drop incoming before the Nov 13 meeting 🔥 Someone is pushing these dates of upcoming NEWS 3 biggest stock alert channels announced, might consider to add now, who knows. $CYTK $CORT

insiderbuyingselling Posted - 2 weeks ago

$CYTK new insider selling: 5000 shares. http://insiderbuyingselling.com/?t=CYTK